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ABSTRACT 
Objective: The objective of the present study was to investigate the stability of TRZ against different stressors and to prepare impurity profile for 
potential impurities and degradation products (DPs) formed under stress degradation of TRZ bulk drug and formulation. 
Methods: Three analytical methods were developed; the stability-indicating method that was developed using HPLC instrument with 0.01M 
ammonium acetate buffer (pH 4.0 using glacial acetic acid (GAA)) and acetonitrile in gradient program. The second method was a UPLC/ESI-MS 
method using 0.1 % Formic acid in Milli Q water (pH= 2.70) and 0.1%Formic acid in Milli Q water: Acetonitrile (10:90) in gradient program for 
identification of TRZ and DPs while the third, preparative HPLC method was used for isolation of impurities using (A) 0.05% ammonia (NH3
Results: The analytical method for stability study was developed and validated using ICH (Q2) R1 guidelines. The result of stability study by stress 
degradation showed that TRZ was susceptible to degradation in acid (7 DPs), alkaline, neutral (9 DPs) and oxidative conditions (10 DPs); major DPs 
were identified (where it was possible) and the chemical structure was elucidated by combining the data of ESI/MS, NMR and/or Tandem MS. The 
Impurity profiling was completed by reporting all the DPs, either major or minor for TRZ bulk drug and formulation.  
) in 
water and (B) Acetonitrile+20% mobile phase A in gradient sequence. Gradient sequences are described in the main text. 
Conclusion: The complete Impurity profiling for TRZ is reported for the first time in literature. The study data would be add-on for formulation 
storage condition and further development.  
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INTRODUCTION 
Research of novel therapeutic treatment for TB cure is the interesting 
and challenging topic for researchers since the TB bacteria M. 
tuberculosis was identified by Dr. Robert Koch in 1882 [1]. The reports 
show that in 2019 third-highest HIV negative TB death mortality was 
observed in India. All over world, 1.2million people died due to TB 
infections (HIV positive and negative) [2]. It shows that survival 
pattern of bacteria are developed against the antibiotics in human 
body, therefore, bacteria are resistant to certain antibiotics and 
remains ineffective by those anti-TB drugs; therefore microbiologist 
and researchers are still working on century-old disease and bacteria. 
Terizidone was approved by CDSCO (Central drugs standard control 
organization) of India in 1981 for treatment of TB, which is 
synthesized by combining two molecules of D-Cycloserin using a 
benzene ring. The chemical structure of TRZ is shown in fig. 1. (A and 
B refers to the D-cycloserin rings)TRZ is indicated in MDR-TB 
(Multidrug resistance TB) [3].  
 
 
Fig. 1: Chemical structure of Terizidone 
The extensive literature survey shows several reported methods 
which are; UV method [4], HPLC method for TRZ in plasma [5], 
stability study for TRZ [6] (degradation products were not separated 
nor reported), the two degradation products of TRZ are reported by 
HPTLC and MS/MS method [7] (the DPs are marked with an asterisk 
in paper and cited which are reported in literature), HPTLC and 
LC/MS/MS methods are reported [8]. None of the reported 
literature investigates the entire impurity profile for TRZ, therefore 
it was an opportunity and challenge to study stress degradation and 
report the impurity profile of TRZ. In this study, the novel DPs and 
process-related impurities are extensively studied and reported in 
the literature for the first time. The objective of the study was to 
study stress degradation and prepare an impurity profile of TRZ. 
MATERIALS AND METHODS 
Chemicals and reagents 
TRZ bulk drug was obtained as a gift sample from Macleods Pharma 
Pvt. Ltd. (Gujarat, India). HPLC grade methanol and acetonitrile was 
purchased from Rankem Chemicals, Gurugram, India. Ammonium 
acetate buffer was purchased from Loba Chemicals Pvt. Ltd, Mumbai, 
India. Glacial acetic acid (>99.0% purity), ammonia and NMR grade 
deuterated Di-Methyl Sulph Oxide (DMSO) were procured from 
Sigma-Aldrich (USA). UPLC/ESI-MS (Ultra Performance Liquid 
Chromatography/Electron Spray Ionization-Mass Spectrometer) 
grade acetonitrile was purchased from Fisher Scientific chemicals, 
India. Formic acid was purchased from Merck, USA. Analytical grade 
hydrochloric acid (HCl) and sodium hydroxide (NaOH) were 
procured from SD Fine Chem. Ltd., Mumbai. Hydrogen peroxide 
(H2O2
Unless and otherwise specified, all solutions were filtered through a 
0.45 µm Nylon 6,6 membrane filter, Ultipore® N66® From Pall Life 
Sciences, USA; prior to use.  
) was procured from Fischer Ltd., India. The water for studies 
was prepared by deionization of water in the laboratory. 
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UV spectrophotometer 
The suitable wavelengths for estimation of API were identified by 
scanning over the range of 200-400 nm with a Shimadzu UV-1700 
double beam Spectrophotometer (Shimadzu, Japan), which contains 
double beam optics with scanning range 190-800 nm with maximum 
stray light of 0.04%and wavelength accuracy±0.3 nm, spectral band 
width was 1 nm, scanning speed approx. 3000 nm/min with silicone 
photodiode detector.  
Liquid chromatographic system 
The HPLC (High-Performance Liquid Chromatographic) system 
consisted of manual injector, low pressure gradient flow control 
valve, solvent delivery module, photodiode array(PDA) detector, and 
system controller with Empower-2 Software (all from Waters 
Acquity Corporation, Milford, MA, USA). For method development, 
the separation was accomplished on a Thermo scientific RP-C18
Method 
 
column (250×4.6 mm, 5 µm) at wavelength 270 nm. The analysis 
was performed at ambient temperature with manual sample loading 
of 20 µl. The mobile phase was filtered through 0.22 µm disposable 
filters (Ultipore®, PALL Life sciences, USA), and degassed with 
provisional ultra sonicator prior to use.  
Stability indicating method was developed to achieve maximum 
possible separation between degradation products and TRZ bulk 
drug-using A) 0.01M ammonium acetate buffer pH 4.7 with glacial 
acetic acid and B) acetonitrile as mobile phase ran in gradient mode. 
The gradient Program used for the separation is shown as time 
(min.)/% A; 0/95, 10/95, 50/70, 55/95, 60/95, flow rate was 1 
ml/min. 
UPLC-MS 
Study was completed on Waters Acquity UPLC with quaternary 
solvent manager with PDA detector, column oven, Acquity ESI 
performance mass detector and autosampler. Mass analysis was 
carried out on single quad mass spectrometer equipped with Waters 
jet stream Electron Spray Ionization (ESI) source with positive mode 
(Waters corp. USA). Mass Lynx software was used for the UPLC-PDA 
and UPLC/ESI-MS data acquisition and analysis of TRZ and its DP.  
UPLC/ESI-MS study was carried out using mobile phase a) 0.1 % 
formic acid in Milli Q water (pH= 2.70) and b) 0.1% formic acid in 
Milli Q water: acetonitrile (10:90). Gradient elution program was set 
to T/(%A) = 0 min (97%) flow: 0.8 ml/min; 0.75 min (97%); 2.7 min 
(2%); 3 min (0%); 3.5 min (0%); 3.51 min (97%); end of run at 4 
min (97%), Flow rate: 1 ml/min, analysis time 4 min. 
Mass probe (Probe temperature 400 °C) was set as source for 
electrospray ionization in positive mode (temp. 120 °C) with cone 
voltage 10 and 30V and capillary voltage 3.25kV. Cone gas flow and 
desolvation (400 °C) gas flow was 100 and 800L/hr, respectively. 
Column and autosampler temperature was set to 35° and 5 °C, 
respectively.  
Preparative HPLC 
The major acid stress degradation was isolated using preparative 
HPLC: Waters 2489 binary, autosampler and auto fraction collector, 
high pressure mixing chamber, and UV detector. Rheodyne injector 
was used to load a sample in chromatographic system.  
The major acid stress degradation product was isolated using 
stationary phase YMC Actus Triart (C 18,  250×20 mm, 5μ) column set 
to ambient temperature. Mobile phase consisted of a) 0.05% 
ammonia (NH3
MS/MS data were obtained on system (Thermoscientific, USA) with 
MS plus pump and autosampler. TSQ Quantum access max mass 
spectrometer was used for analysis. The MS system used spray 
electron ionization in positive mode with voltage 3500V, Capillary 
temperature was 300 °C. The Mass transition was observed for M1 
and M2 level with collision energy 34 eV for both transition. Xcalibur 
Software was used for data analysis (Thermo Fisher, USA). 
) in water and b) acetonitrile+20% mobile phase A 
with flow rate 18.0 ml/min, PDA detection at 270 nm. Gradient 
elution program was set as follows; run time 23 min; T (min) =% v/v 
A: 0.01(100 %), 2 (100%),17.0 (90%),17.01 (2%), 20 (2%), 20.1 
(100%) and stop command after 23 min (100%).  
NMR: NMR was performed on Bruker 400MHz NMR spectrometer 
using deuterated dimethyl sulphoxide (DMSO-d6) and D2
Precision Water/Oil bath (EIE, India) with temperature controller 
equipment was used for stress degradation studies to maintain 
temperature of samples.  
O 
(deuterated water) as solvent. Chemical shifts were recorded in ppm 
(𝛿 Scale) and coupling constants in Hertz against TMS (0𝛿 ppm) as 
an internal standard. For data analysis Top spin software 3.2 was 
used.  
Photolytic degradation study was carried out in a photostability 
chamber (Thermolab Scientific Equipments Pvt Ltd, Vadodara) 
Equipped with a light back consisting of four UV (OSRAM L73) and 
Fluorescent (OSRAM L20) lamps, that complied with specifications 
prescribed in the ICH guideline Q1B. The system is capable of 
controlling specific temperature and humidity (±2 °C and±5% RH). 
Other equipments used were an Ultrasonic bath (Analab Scientific 
Instruments Pvt Ltd, Vadodara), Precision analytical balance (AX 
120, by Shimadzu Corporation analytical and measuring 
instruments division, Kyoto, Japan.), pH Meter (Lab India 
Instruments Pvt Ltd., Navi Mumbai). The analysis of data and 
Calculations were done using Microsoft Excel-2007. 
Sample preparation 
TRZ (accurately weighed 500 mg) was dissolved in 3 ml DMSO and 
sonicated for 15 min with provisional shaking; 50 ml final volume 
was achieved using 6% hydrogen peroxide, 0.5N HCl, 0.5N NaOH 
and water (final concentration 100 mg/ml) individually. At regular 
time interval aliquot of 2 ml was withdrawn from the 0 minute to till 
the degradation in TRZ was observed, the sample was kept in dark 
and diluted to 10 ml with methanol (20 mg/ml), filtered through 
0.45 μ Pall syringe filter and injected in chromatographic system 
described in section materials and methods in RP-HPLC for data 
acquisition and analytical purpose.  
TRZ was stressed under different conditions so that 5-100% 
decreases in peak area of TRZ bulk drug could be noticed. Marketed 
formulation of TRZ (Tericox, Macleods Pharma Pvt. Ltd.) was treated 
similar degradation conditions as performed for bulk drug-using 
tablet powder equivalent to 10 mg of TRZ to determine the 
formation of any DPs due to drug–excipient, drug-stressor or 
stressor-excipient interaction.  
Stress degradation study 
The stress degradation of TRZ was investigated under hydrolytic 
solutions (acid, alkali and water), in oxidative medium, under 
thermal condition and photolytic condition. TRZ degraded 
significantly in hydrolytic solutions (acid and water) and oxidative 
solution while it remains stable in thermal and photolytic 
conditions. There was no major DP in alkaline conditions; instead, 
several fractions of TRZ were obtained, shown in fig. 2 (D), and 
therefore no DPs are reported. The results for stress degradation 
study are shown in table 1.  
Isolation of DPs 
The major DP was identified by the maximum % area covered by the 
DP peak in HPLC chromatogram with peak purity. The degradation 
impurity was isolated using preparative HPLC; instrumental and 
chromatographic specifications are described in section materials 
and methods. 
High concentration sample was prepared for isolation: accurately 
weighed 5 gm of TRZ was dissolved separately in 15 ml methanol 
with provisional shaking for 15 minutes by sonication; 50 ml final 
volume was achieved using 0.5N HCl, water and 6% H2O2, the 
solution was kept in specified stability conditions in the dark (0.5N 
HCl at RT for 24 h, water at RT for 24 h and 6% H2O2 at RT for 5 h). 
Aliquot of 2.6 ml sample load (0.6 ml vial+1 ml water+1 ml 
methanol) was injected in described chromatographic condition of 
preparative HPLC. The fractions were collected separately and 
combined to concentrate the fraction by removing organic solvent 
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on rotavapor and washing with water to remove the buffer used in 
the mobile phase. The concentrated sample was again injected in 
system to check against purity and for other co-eluting substance 
presence. The concentrated sample was freeze-dried to get a solid 
after confirmation of purity>98.0 % by HPLC. This final product was 
analyzed for LC/ESI-MS and NMR (1H, 13
RESULTS 
C and APT (Attached proton 
Test)) or MS/MS.  
Degradation behavior of TRZ 
TRZ undergoes degradation in hydrolytic solution and in the 
presence of an oxidative agent. The process-related impurity was 
observed with bulk drug chromatogram, the chromatograms 
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Fig. 2: HPLC Chromatogram for A) Specificity of Method B) Selectivity of method C) Acid degradation of TRZ D) Alkaline degradation of 
TRZ E) Water degraded TRZ F) Oxidation of TRZ 
 
The DPs formed in these conditions were identified and major DPs 
were characterized using NMR and/or MS/MS. Peaks were 
evaluated against peak purity tests and % area occupied in the 
chromatogram (% Mass balance of 100) is shown in table 1. 
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Table 1: Stress degradation report of TRZ by HPLC 
DPs and R Purity angle t Purity threshold % Area 
(B)* TRZ bulk drug 
** 0.168 Peak: 20.11 0.565 5.30 
API Peak-28.11 0.117 0.246 94.70 
(C)*
Peak1: 8.1 
 TRZ acid degradation sample 
1.415 0.281 4.25 
Peak 2:15.3 
(Major DP) 
0.133 0.248 46.79 
Peak 3:15.9 0.241 0.359 1.14 
API: 26.4 0.211 0.303 44.86 
(D)*
Peak1:10.9 
 TRZ neutral degradation sample 
0.241 0.373 2.40 
Peak2: 16.2 
(Major DP) 
0.104 0.241 32.99 
Peak3: 24.9 1.868 1.711 0.43 
API: 26.6 0.188 0.274 62.85 
Peak4: 35.9 1.155 1.300 0.48 
Peak5: 37.0 0.310 0.947 0.84 
(E)*
API: 28.6 
 TRZ alkali sample 
0.086 0.355 3.5 
Peak1:29.6 0.063 0.245 5.5 
Peak2:33.6 0.213 0.287 0.29 
Peak3:34.7 0.257 0.267 7.89 
Cluster of peaks - - 82.82 
(F)*
Peak1: 8.027 
 TRZ oxidative sample 
1.945 1.115 19.11 
Peak2: 15.262 
(Major DP) 
0.237 0.248 46.85 
API: 26.168 0.244 0.248 7.42 
H2O2 1.177 :2.657 3.919 26.62 
*Result for chromatograms shown in fig. 2**
 
 Process related impurity 
Validation of stability indicating method 
The stability-indicating method was validated as per ICH Q2 (R1) 
guidelines [9] in terms of linearity, range, precision and recovery. 
The good linearity was observed for the range (50-300μg/ml) of 
TRZ with a correlation coefficient of 0.997. RSD (relative Standard 
deviation) for linearity, precision and recovery study was<2.0% 
indicates that a precise and reproducible method was developed. 
The recovery for the study was in the range of 98.4-100.5% 
indicates that good recovery was obtained. The assay result showed 
that 99.5% recovery of the formulation was observed. The validation 
results are shown in table 2. The overlay of different concentrations 
of TRZ solution for linearity is shown in fig. 3. 
Major degradation products  
The major degradation products were observed in acid, neutral and 
oxidative condition which was isolated for identification and 
characterization purpose. 
Confirmation of isolated DP 
The method for isolation of DP is described in the previous section. 
The isolated DPs were confirmed by HPLC and ESI/MS to check 
whether desired DP was isolated. The HPLC chromatogram and 
ESI/MS spectrum for isolated DPs of acidic, neutral and oxidized 
TRZ is shown in supplementary file S1. 
Characterization by NMR and/or tandem MS 
The characterization of isolated DP was done using NMR and/or 
Tandem MS to evaluate the structure of DP. Tandem MS spectrum 
and fragmentation pathway is shown in supplementary file S2 for 
acid, neutral and oxidative conditions. 
The characterization for isolated DP was completed by NMR studies for 
acid (4H) and oxidative DP (O1),1H NMR, for neutral DP-(3A), 1H, 13
  
C and 
APT NMR (Supplementary file S3) was performed. The assignment of 
NMR spectrums is shown in table 3 for acid, neutral and oxidized DP. 
Table 2: Validation of stability indicating method of TRZ 
Parameters Results 
Linearity  
Regression equation y = 57453x+6E+06 
Co-relation Coefficient 0.997 
Range (μg/ml) 50-300 
RSD (%) <2.0% 
Precision  
Repeatability (%RSD) 0.982 
Intraday Precision (%RSD) 0.920 
Inter-day Precision (% RSD) 0.791 
Recovery 
Recovery range (%) 98.4-100.5 
LOD (μg/ml) 4.23 
LOQ (μg/ml) 13.2 
 
Rajput et al. 
Int J Pharm Pharm Sci, Vol 13, Issue 5, 83-95 
88 
 
Fig. 3: Overlay chromatogram of TRZ and linearity plot 
 
Table 3: NMR assignment for isolated major DP of oxide, acidic and neutral condition 
Chemical shift (∂, ppm) (Multiplicity) 
α-position API O1 4H 3A 
  1H 1H 1H 13 APT C 
1 7.88(s) *7.64 (m) 7.8(m) 7.6(s) 128.0 -CH(uf) 
2 7.88(s) *7.64 (m) 7.6(m) 7.6(s) 128.0 -CH(uf) 
3 C - C C 133.5 -C(lf) 
4 7.88(s) 7.64 (m) 7.8(m) 7.8(s) 128.0 -CH(uf) 
5 7.88(s) - 7.6(m) 7.6(s) 128.0 -CH(uf) 
6 C *4.26(brs) C C 133.5 -C(lf) 
7 8.5(s) 8.31 (m) 8.4(s) 8.4(s) 150.4 -CH(uf) 
8 8.5(s) 8.31 (m) 8.4(s) 8.4(s) 150.4 -CH(uf) 
9 N - N N - - 
10 N - N N - - 
11 4.6(m) *- 4.3(m) 4.5(m) 52.6 -CH(uf) 
12 4.6(m) *- 4.3(m) 4.5(m) 52.6 -CH(uf) 
13 C *2.05(s) - - 169.5 -C(lf) 
14 O *4.4 (brs) *11.7(brs) - - - 
15 N - *10.0(s) *4.3(brs) - - 
16 4.4,4.5 (t) *4.4 (brs) 4.5(m) 4.5(m) 39.3 -CH(lf) 
17 4.4, 4.5(t) *4.4 (brs) 4.5(m) *2.4(m) 39.3 -CH(lf) 
18 N - *1.5(s) *4.3(brs) - - 
19 O *7.7 (m) - - - - 
20 C - - - 159.5 -C(lf) 
21 O - - - - - 
22 O - - - - - 
23 - - - - 71.2 -2CH(lf) 
24 - 11.60 (s) (OH) - *4.4(m) 71.2 -2CH(lf) 
25 11.60 (s)(OH) - - *4.3 (s) - OH 
Values with asterisk (*) indicates changes observed in spectrum/lf=Lower field Up=Upper field in C13
 
NMR, the elucidated structures for DP are 
shown in fig. 4 
Impurity profiling  
The impurities were identified by m/z ion of [M+H]+ of ESI-MS 
spectrum, high concentration sample was used to reduce S/N (signal 
to noise) ratio and better signals. The reporting threshold for 
impurity is 0.5% (1000 mg daily dose-<2g/day dose) and the 
identification threshold is 1% of TRZ daily dose.  
Process related impurity 
The chromatogram of TRZ bulk drug showed process-related 
impurity which covered 5.30% of total area. The UPLC 
chromatogram and ESI/MS spectrum are shown in supplementary 
file S4. The ESI/MS spectrum of TRZ showed base peak of 391.5 m/z 
that indicates that adduct was formed with formate ion [M+Formic 
acid (88)+H+
Acid degradation products  
]. The m/z for process-related impurity was 116.4 amu. 
The proposed structure for process-related impurity is shown in fig. 
4 (E).  
Degradation impurity identification by ESI/MS: The sample 
containing a mixture of DPs in acid solution was targeted for UPLC-
ESI/MS to identify the minor DPs present in the sample along with 
major DP. The UPLC chromatogram and ESI/MS spectrum for peaks 
are shown in fig. 5. DPs are named as 1H to 7H where H stands for 
acid HCL. 
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Fig. 5: UPLC chromatogram and ESI-MS spectrum for TRZ behavior in acid condition 
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The peaks in fig. 5 are showing broadening and tailing, as high 
concentration sample was used for analysis to detect the very low 
responses in ESI/MS. The ESI-MS spectrum showed seven DPs, 
among which one was major DP (4H) and other DPs were eluted at 
Rt 0.198, 0.669, 0.981, 1.204, 1.278 1.495 and 1.863. The name of 
the DPs are mentioned in the increasing order of m/z for DPs; DP-
1H (m/z 417 Rt, 0.198), DP-2H(m/z 161 co-elution with m/z 116 
Impurity-1, Rt, 1.863), DP-3H(m/z 170 Rt,0.664), DP-4H (m/z 
237.2,Rt,0.956,0.981, 1.029), DP-5H(m/z 279, Rt, 1.204), DP-
6H(m/z 283, Rt, 1.278)(reported in literature [8]) and DP-7H(m/z 
455, Rt, 1.495). The data is gathered in table 4 with the proposed 
structure. 
  
Table 4: MS spectrum analysis and DP identification in acid medium 
DP with Rt m/z Chemical structure and name Chemical formula 
DP-1H (0.198) 417 
 
(3’s, 4R)-4-(((E)-(((3S, 4S)-3-(hydroxymethyl)-5-oxoisoxazolidin-4-yl) imino) 






































(3R, 2S)-4-((E)-4-((E), (((3R, 4R)-5-oxo-3-phenylisooxazolidin-4-
yl)imino)methyl)benzylidene)amino)-3-phenylisoxazolidin-5-one 
C26 H22 N4 O4 
*reported in the literature [8], the possible mechanism for the formation of DP is discussed in the next section. The possible degradation pathway 
for TRZ in acid media is shown in fig. 6. 
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DP-1H 
The m/z base value in DP-1H is 157.1, which is common background ion 
found in MS study that belongs to the DMSO [2M+H]+ while DP-1 m/z is 
417.3. The DP can be formed by conjugation between TRZ API and other 
Enantiomeric fragments of TRZ API with amine group of five-member 
ring while on another side–O-CH2 group attached with amine group of 
the five-member ring. The attachment sight for TRZ is position C15and17 
and N14and18
DP-2H 
. The DP-1 is formed due to addition of groups. 
DP-2H is formed due to the degradation of a five-member ring 
attached to Enantiomeric carbon at α–position 7 and 8. Another MS 
peak shown along with DP-2 is of process-related impurity, which is 
identified in previous section. The cleavage between position C-8 
and N-10 and between N-9 and C-11 formed DP-2H. 
DP-3H 
The m/z for DP-3H is 170.1 which suggest the degradation of 
benzene ring and five-member ring in TRZ structure. Another MS 
peak of 79 is because of solvent DMSO [M+H]+.  
DP-4H 
DP-4H is a major DP with m/z of 237.0; identification and 
characterization is described in details in the previous section. The 
DP-4H is formed due to the cleavage of five-member rings. Amine 
groups of five member ring remains attached while alcohol and 
ketone group is removed due to acid effect. The alcohol group 
remains attached to the amine in one of the side and it was 
confirmed by proton NMR spectrum analysis [11]. 
DP-5H 
DP-5H is formed due to the degradation of five-member ring, the 
alcohol group remains attached on both side and one more alcohol 
group remains attached to one of the side while other groups are 
removed due to acid-catalyzed reaction.  
*
The DP-6H is formed due to removal of alcohol and amine and 
ketone group from five-member rings of TRZ chemical structure. 
The ketone group in one of the side remains attached with five-
member ring. The DP is reported in the literature however, in this 
study DP-6H is minor DP.  
DP-6H 
DP-7H 
The DP-7H is formed due to the attachment of benzene rings at 
attachment sites in TRZ chemical structure. The benzene ring is 




Fig. 6: Degradation pathway of TRZ in acid media 
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Alkaline degradation products 
Several fractions were formed in alkaline condition after 
degradation of TRZ and ESI/MS spectrum showed several peaks for 
fractions. It was not possible to report all of them and there was no 
intense or major peak that can be considered as major or reportable. 
The pattern for degradation of TRZ in alkaline condition was in 0.5N 
NaOH at RT, TRZ peak appeared for 35 min after 35 min the 
fractions shown in fig. 2 were observed, for lower concentration the 
degradation time point was extended but the same chromatogram 
was obtained.  
Aqueous degradation products 
The TRZ bulk drug was degraded in water at RT in the dark and it 
formed five new peaks in TRZ HPLC chromatogram among which one 
major DP was formed at Rt16.02 min while one DP was formed at Rt 
24.02 min showed co-elution of substance with it. The DPs formed in 
neutral degradation study was less than the identification and 
reporting threshold except for DP-1A and DP-2A. For that reason in 
UPLC-ESI/MS spectrum, the data shown the mass peak without co-
elution was identified and other mass clusters were reported. 
Degradation impurity identification by ESI/MS: The UPLC 
chromatogram for TRZ neutrally degraded sample is shown in fig. 7 
with mass peaks. 
The peak at Rt 0.697, 0.905 and 0.988 were single eluted peaks 
therefore identified. DP at 0.988 was a major DP. The clusters of 
mass peaks are reported in the degradation pathway. The analysis of 
the mass spectrum is shown in table 5. The DPs are named as DP-1A 





Fig. 7: UPLC chromatogram and ESI-MS spectra for TRZ behavior in neutral media 
 
Table 5: Mass spectrum analysis of TRZ in neutral media 



















imino) methyl) benzylidene) isoxazolidin-4-aminium 
C16H19N4O5 
Three DPs those were single eluted, identified for neutral degradation of TRZ. The m/z of clusters is reported in the proposed degradation pathway 
and mechanisms for the formation of DPs are described below; the proposed degradation pathway is shown in fig. 8. 
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Fig. 8: Proposed degradation pathway for TRZ in neutral media 
 
DP-1A 
The DP-1A is formed due to the removal of a five-member ring from 
side A and on another side (B) removal of ketone (=O), alcohol (-O) 
and amine (-NH2
DP-2A 
) group. The hydrolysis of TRZ formed DP-1A from 
the source DP-2A.  
The DP-2A showed m/z 219, which suggest the removal of five-
member ring attached to amine group. The cleavage of bond 
between amine (-NH) and carbon of five-member ring formed the 
DP-2A. The hydrolysis of TRZ was the mechanism for formation of 
DP-2A  
DP-3A 
The attachment of the methoxy group at position C-17 resulted in 
the formation of DP-3A (major DP). TRZ was not stable in 
proteolytic solution and formed a number of DPs. The attachment 
may be result of constant conformational change, which stabilized in 
the form of DP-3A.  
Oxidized degradation products 
TRZ was kept in the presence of oxidative agent to notice any 
change in TRZ chemical structure by observing the change in HPLC 
chromatogram. The chromatogram showed two additional peaks 
other than TRZ and hydrogen peroxide peak. Major peak-2 was 
passed in purity test and was isolated by preparative HPLC, 
identified by ESI/MS and Tandem MS, characterized by proton 
NMR. The co-eluting substances in peak-1 were identified by 
ESI/MS. 
Degradation impurity identification by ESI/MS: Identification of DP 
was carried out by ESI/MS. The UPLC chromatogram and ESI/MS 
spectrum is shown in supplementary file S5. The UPLC 
chromatogram showed 11 mass peaks among which one was major 
DP which has m/z 323.3. The ten DPs were eluted in HPLC 
chromatogram at Rt 8.027 min. The DPs with m/z 170 (3H), 417 
(1H) and 237 (4H) are already identified in acid medium while other 
DPs are not identified as the mass peaks appeared as cluster with 
low percentage of area covered by peaks.  
The major DP with m/z 323.1 suggests the oxidation of TRZ. The 
oxidation in presence of oxidizing agent was occurred at position 22 
and 17 in TRZ chemical structure. The conjugation or/and 
fragmentation of TRZ formed other minor DPs. The Oxide DP (O1) is 
named as (4S, 5S)-5-hydroperoxy-N-((E)-4-((E)-(((R)-5-oxo-1,3,2-
dioxazolidin-4-yl)imino)methyl)benzylidine)isoxazolidin-4-aminium 
that matches with chemical formula C13H15N4O6
The proposed degradation pathway is shown in fig. 9. 
.  
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Fig. 9: Proposed degradation pathway for TRZ in oxidative media 
 
DISCUSSION 
The analytical method developed for stability study was accurate, 
precise and sensitive enough to detect low concentration of impurity 
in TRZ sample. The validation of method was successfully completed 
applying ICH Q2 (R1) guideline, which suggest the RSD value<2.0% 
for linearity, precision and accuracy study.  
The stress degradation study revealed that TRZ was liable to 
degradation in hydrolytic solutions and in presence of oxidative 
agent while TRZ was chemically stable in thermal condition and 
under UV light for more than 21 d, although color change from white 
to pale yellow was visualized without chemical change in TRZ. 
Process-related impurity or inherent impurities may be present in 
API due to incomplete reaction during synthesis or the by-product of 
synthesis reaction of bulk drug. This impurity may or maybe not 
take part in chemical reaction of bulk drug. During synthesis of TRZ 
bulk drug, cleavage between Enantiomeric carbon (C7) and benzene 
ring carbon (c6) resulted in incomplete reaction and formed 
Impurity-1 (process-related impurity). The m/z of impurity-1 
obtained by UPLC/ESI-MS was 116 amu which is matching with the 
chemical formula C4H8N2O2.
CONCLUSION 
[10]In acid media,for degradation of 
TRZ, acidic environment was liable, which resulted in formation of 7 
DPs (1H-7H). The DPs were result of the cleavage of bonds where 
acid was appearing as catalyst. The major DP-4H was the result of 
hydrolysis in the presence of acid. If TRZ is not treated for a longer 
duration in acid (such as gastric acid in the human body), 
degradation products will start to form that might be biologically 
active, have toxic or adverse effects. Therefore it is recommended to 
coat TRZ formulation with a suitable agent or to improve the 
solubility of TRZ in water. In neutral media (water), TRZ bulk drug 
undergone hydrolysis and methylation to form 10 DPs (1A-10A) 
among which three DPs were noticeable (1A-3A). TRZ is highly 
reactive in aqueous solutions; therefore, it is recommended to form 
a stable salt of TRZ to avoid the degradation of TRZ in water. The 
oxidative agent reacts with TRZ to form a degradation product of 
oxidation reaction. It is recommended to avoid any oxidizing agent 
during the production of formulation or during the course of storage 
of TRZ bulk drug or formulation. TRZ is highly susceptible for 
alkaline medium. The study suggests taking high precautions during 
formulation production as well as in the storage of bulk drug and 
formulation to avoid unwanted reaction or degradation of TRZ.  
The stability study for TRZ was performed and it was observed that 
TRZ degraded in acid, neutral, alkaline and oxidative medium while 
stable under UV and thermal conditions. TRZ was highly sensitive 
for alkaline media. The major DPs were isolated, identified and 
characterized using different sophisticated instruments. While 
minor DPs present in sufficient quantity to fall in the category of 
classification of identification of impurity was identified using 
ESI/MS spectrum. The process-related impurity and other 
degradation impurities are reported for the first time. The study 
results are handy material for suggested storage conditions and 
improvement in formulation development.  
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